Summarized by Masters of Longevity from Longevity Technology.
GLP-1 research at a major aging conference — a concise preview of industry presentations exploring biological‑age biomarkers and modeled lifespan effects.
Key Takeaways
- Novo presented semaglutide cohort modeling that projected an average remaining life-year gain of 1.9 years across age groups.
- Lilly reported epigenetic sub-study results where multiple methylation clocks indicated less biological aging over 72 weeks.
- Both companies emphasized early, caveated findings and the need for larger controlled trials to validate longevity claims.
